Search

The measurement of virus-specific neutralising antibodies represents the "gold-standard" for diagnostic serology. For animal morbilliviruses, such as peste des petits ruminants (PPRV) or rinderpest virus (RPV), live virus-based neutralisation tests require high-level biocontainment to prevent the accidental escape of the infectious agents. In this study, we describe the adaptation of a replication-defective vesicular stomatitis virus (VSVΔG) based pseudotyping system for the measurement of neutralising antibodies against animal morbilliviruses. By expressing the haemagglutinin (H) and fusion (F) proteins of PPRV on VSVΔG pseudotypes bearing a luciferase marker gene, neutralising antibody titres could be measured rapidly and with high sensitivity. Serological responses against the four distinct lineages of PPRV could be measured simultaneously and cross-neutralising responses against other morbilliviruses compared. Using this approach, we observed that titres of neutralising antibodies induced by vaccination with live attenuated PPRV were lower than those induced by wild type virus infection and the level of cross-lineage neutralisation varied between vaccinates. By comparing neutralising responses from animals infected with either PPRV or RPV, we found that responses were highest against the homologous virus, indicating that retrospective analyses of serum samples could be used to confirm the nature of the original pathogen to which an animal had been exposed. Accordingly, when screening sera from domestic livestock and wild ruminants in Tanzania, we detected evidence of cross-species infection with PPRV, canine distemper virus (CDV) and a RPV-related bovine morbillivirus, suggesting that exposure to animal morbilliviruses may be more widespread than indicated previously using existing diagnostic techniques., (Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.)

After the 2011 declaration of rinderpest disease eradication, we surveyed 150 countries about rinderpest virus stocks. Forty-four laboratories in 35 countries held laboratory-attenuated strains, field strains, or diagnostic samples. Vaccine and reagent production and laboratory experiments continued. Rigorous standards are necessary to ensure that stocks are kept under safe conditions.

Rinderpest is only the second infectious disease to have been globally eradicated. In the final stages of eradication, the virus was entrenched in pastoral areas of the Greater Horn of Africa, a region with weak governance, poor security, and little infrastructure that presented profound challenges to conventional control methods. Although the eradication process was a development activity rather than scientific research, its success owed much to several seminal research efforts in vaccine development and epidemiology and showed what scientific decision-making and management could accomplish with limited resources. The keys to success were the development of a thermostable vaccine and the application of participatory epidemiological techniques that allowed veterinary personnel to interact at a grassroots level with cattle herders to more effectively target control measures.

The global eradication of rinderpest was declared in 2011. This is the second infectious disease to have been eradicated from the world after smallpox, for which eradication was declared in 1980. From a scientific aspect, smallpox eradication was achieved by improvements in the Jenner vaccine, originally developed in the 18th century. Developments in vaccine technology and virological techniques during the 20th century have contributed to the eradication of rinderpest. The scientific background to rinderpest eradication is briefly reviewed vis-à-vis that of smallpox eradication., (Copyright © 2012 Elsevier B.V. All rights reserved.)

The mononegaviruses include a number of highly contagious and severe disease-causing viruses of both animals and humans. For the control of these viral diseases, development of vaccines, either with classical methods or with recombinant DNA virus vectors, has been attempted over the years. Recently reverse genetics of mononegaviruses has been developed and used to generate infectious viruses possessing genomes derived from cloned cDNA in order to study the consequent effects of viral gene manipulations on phenotype. This technology allows us to develop novel candidate vaccines. In particular, a variety of different attenuation strategies to produce a range of attenuated mononegavirus vaccines have been studied. In addition, because of their ideal nature as live vaccines, recombinant mononegaviruses expressing foreign proteins have also been produced with the aim of developing multivalent vaccines against more than one pathogen. These recombinant mononegaviruses are currently under evaluation as new viral vectors for vaccination. Reverse genetics could have great potential for the preparation of vaccines against many mononegaviruses., (Copyright © 2011 Elsevier B.V. All rights reserved.)

This paper describes the improvement of a rapid diagnostic test for the detection of rinderpest virus (RPV) at pen-side and the development of a similar test for the detection of another Morbillivirus, peste de petits ruminants virus (PPRV). Using the Svanova Biotech format, prototype chromatographic strip test devices were developed for RPV and PPRV detection. For the RP device, the incorporation of a monoclonal antibody (Mab), which recognises additional RPV strains of RPV lineage 2, enhanced the range of reactivity of the rapid diagnostic test. The device detected antigen in animals infected experimentally with different RPV strains. It also showed detection levels similar to the RP Clearview™ device reported previously. In addition, RPV was also detected under field conditions in Pakistan. A PPRV specific Mab (C77) was used for the development of the PPR test. This Mab recognised a wide range of PPRV isolates and did not show any cross-reactivity with any other virus tested. In animal experiments the device was able to detect viral antigen in eye swabs taken from the animals. The PPRV test should be invaluable for future PPR control eradication programs., (Copyright © 2011 Elsevier B.V. All rights reserved.)

A cross-sectional sero-survey, using a two-stage cluster sampling design, was conducted between 2002 and 2003 in ten administrative regions of central and southern Somalia, to estimate the seroprevalence and geographic distribution of rinderpest (RP) in the study area, as well as to identify potential risk factors for the observed seroprevalence distribution. The study was also used to test the feasibility of the spatially integrated investigation technique in nomadic and semi-nomadic pastoral systems. In the absence of a systematic list of livestock holdings, the primary sampling units were selected by generating random map coordinates. A total of 9,216 serum samples were collected from cattle aged 12 to 36 months at 562 sampling sites. Two apparent clusters of RP seroprevalence were detected. Four potential risk factors associated with the observed seroprevalence were identified: the mobility of cattle herds, the cattle population density, the proximity of cattle herds to cattle trade routes and cattle herd size. Risk maps were then generated to assist in designing more targeted surveillance strategies. The observed seroprevalence in these areas declined over time. In subsequent years, similar seroprevalence studies in neighbouring areas of Kenya and Ethiopia also showed a very low seroprevalence of RP or the absence of antibodies against RP. The progressive decline in RP antibody prevalence is consistent with virus extinction. Verification of freedom from RP infection in the Somali ecosystem is currently in progress.

Fading immune protection in farmed animals may present a problem, particularly in free-ranging animals in nomadic and transhumant pastoral systems, where animals are not readily available for large-scale blanket vaccination programmes. Two veterinary examples of fading immune protection are discussed: rinderpest and foot-and-mouth disease (FMD). Both are devastating viral diseases of cattle that have a huge impact on the farming economy. Both diseases can be controlled by vaccination, although the post-vaccination immunity afforded by the rinderpest vaccine is markedly different from that induced by FMD vaccines. These differences may in part explain the respective advancement of international eradication campaigns: while global eradication of rinderpest is imminent, FMD viruses are still actively circulating in many parts of the world., (Copyright 2009 Elsevier Ltd. All rights reserved.)

The innate immune response, in particular the production of type 1 interferons, is an essential part of the mammalian host response to viral infection. We have previously shown that rinderpest virus, a morbillivirus closely related to the human pathogen measles virus, blocks the actions of type 1 and type 2 interferons. We show here that this virus can also block the induction of type 1 interferon. The viral non-structural C protein appears to be the active agent, since expressing this protein in cells makes them resistant to activation of the interferon-beta promoter while recombinant virus that does not express the C protein activates this promoter much more than virus expressing the C protein. In addition, differences in activation of the interferon-beta promoter by different strains of rinderpest virus are reflected in differing abilities of their respective C proteins to block activation of the promoter by dsRNA. The C protein blocks the activation of this promoter induced by either cytoplasmic dsRNA or by Newcastle disease virus (NDV) infection, as well as activation induced by overexpression of several elements of the signalling pathway, including mda-5, RIG-I and IRF-3. The RPV C protein also blocks transcription from promoters responsive individually to the three transcription factors that make up the interferon-beta promoter enhanceosome, although it does not appear to block the activation of IRF-3.

This chapter deals with relatively simple ways to use control charts to monitor the performance of ELISAs. A rinderpest competition ELISA, for the estimation of antibodies in serum samples, is used to demonstrate the methods. This assay is available in a kit form. Constant evaluation of the use of the kit is part of what is called internal quality control (IQC). Figure 1 shows an overview of the ELISA scheme described in this chapter. The details of the procedure, which involves plotting the data graphically (charting methods), are explained herein. The objectives of charting data are as follows: 1. To keep a constant record of all data. 2. To monitor the assay from plate to plate in any one day's testing. 3. To monitor the tests made from day to day, week to week, year to year. 4. To allow rapid identification of unacceptable results. 5. To allow recognition of reagent problems. 6. To identify trends in results (increasingly poor performance). 7. To identify when a new set of kit reagents is necessary. 8. To allow identification of differences among operators of the assay. 9. To fulfill various criteria for good laboratory practice. 10. To fulfill necessary requirements for external recognition to prove that tests are being performed at an acceptable level (increasingly important when results are used for international trading purposes).

The nucleocapsid (N) protein of all morbilliviruses has a highly conserved central region that is thought to interact with and encapsidate the viral RNA. The C-terminal third of the N protein is highly variable among morbilliviruses and is thought to be located on the outer surface and to be available to interact with other viral proteins such as the phosphoprotein, the polymerase protein and the matrix protein. Using reverse genetics, a chimeric rinderpest virus (RPV)/peste-des-petits-ruminants virus (PPRV) was rescued in which the RPV N gene open reading frame had been replaced with that of PPRV (RPV-PPRN). The chimeric virus maintained efficient replication in cell culture. Cattle vaccinated with this chimeric vaccine showed no adverse reaction and were protected from subsequent challenge with wild-type RPV, indicating it to be a safe and efficacious vaccine. The carboxyl-terminal variable region of the rinderpest N protein was cloned and expressed in Escherichia coli. The expressed protein was used to develop an indirect ELISA that could clearly differentiate between RPV- and PPRV-infected animals. The possibility of using this virus as a marker vaccine in association with a new diagnostic ELISA in the rinderpest eradication programme is discussed.

Eight hundred and thirty five serum samples collected from eight wild artiodactyl species in Kenya and Tanzania between 1982 and 1993 were tested for virus-neutralising (VN) antibodies to rinderpest (RP) virus. Antibodies were found in 116 of 344 buffaloes (Syncerus caffer) but not in the other species including 349 wildebeest (Connochaetes taurinus). Most of the antibody positive buffaloes were from the Maasai Mara-Serengeti ecosystem (MM-SE) and would have had opportunity for exposure to the virus during the epidemic of rinderpest in buffalo confirmed there in 1982. Buffalo born after 1985 did not have antibody indicating that virus stopped circulating in this population at or around that time. This second demonstration that RP virus disappears from the MM-SE is further evidence that these species are not permanent reservoirs of this virus. Re-infection of wildlife is transient and they remain valuable sentinels for infection in nearby domestic livestock.

The matrix (M) protein of paramyxoviruses forms an inner coat to the viral envelope and serves as a bridge between the surface glycoproteins (F and H) and the ribonucleoprotein core. Previously, a marker vaccine (RPV-PPRFH) was produced for the control of peste des petits ruminants (PPR) disease, where the F and H genes of Rinderpest virus (RPV) were replaced with the equivalent genes from Peste-des-petits-ruminants virus (PPRV); however, this virus grew poorly in tissue culture. The poor growth of the RPV-PPRFH chimeric virus was thought to be due to non-homologous interaction of the surface glycoproteins with the internal components of the virus, in particular with the M protein. In contrast, replacement of the M gene of RPV with that from PPRV did not have an effect on the viability or replication efficiency of the recombinant virus. Therefore, in an effort to improve the growth of the RPV-PPRFH virus, a triple chimera (RPV-PPRMFH) was made, where the M, F and H genes of RPV were replaced with those from PPRV. As expected, the growth of the triple chimera was improved; it grew to a titre as high as that of the unmodified PPRV, although comparatively lower than that of the parental RPV virus. Goats infected with the triple chimera showed no adverse reaction and were protected from subsequent challenge with wild-type PPRV. The neutralizing-antibody titre on the day of challenge was approximately 17 times higher than that in the RPV-PPRFH group, indicating RPV-PPRMFH as a promising marker-vaccine candidate.

Rinderpest, or cattle plague, is caused by Rinderpest virus (RPV), which is related most closely to human Measles virus (MV), both being members of the genus Morbillivirus, a group of viruses known to have strong immunosuppressive effects in vitro and in vivo. Here, it was shown that peripheral blood mononuclear cells (PBMCs) isolated from cattle experimentally infected with either wild-type or vaccine strains of RPV impaired the proliferation of PBMCs derived from uninfected animals; however, in contrast to either mild or virulent strains of wild-type virus, the inhibition induced by the vaccine was both weak and transient. Flow-cytometric analysis of PBMCs obtained from cattle infected with different strains of RPV showed that the proportion of infected cells was virus dose-dependent and correlated with lymphoproliferative suppression.

Veterinary science has benefited much from the advances in biotechnology during the past 20 years. New and improved diagnostic techniques for infectious diseases have been developed and new and highly effective vaccines to prevent such diseases have been introduced and more have been, or are about to be, field-tested. The latest development in negative strand virology, reverse genetics, the ability to rescue live virus from a DNA copy of the RNA genome, is being used to address questions concerning virus pathogenicity at the molecular level and to produce "marker" vaccines, i.e. vaccines that allow serological identification of all vaccinated animals. Such a vaccine would greatly benefit the continuing campaign for the global eradication of rinderpest since it would then be possible, by serological means, to detect wild type virus circulating in local areas or regions where it is still necessary to vaccinate and where the vaccination levels are below those required to eliminate the virus. Here we describe different approaches we have taken to produce such a vaccine using reverse genetics to add a marker to the existing and widely used Plowright rinderpest vaccine.

A major molecular determinant of virus host-range is thought to be the viral protein required for cell attachment. We used a recombinant strain of Rinderpest virus (RPV) to examine the role of this protein in determining the ability of RPV to replicate in rabbits. The recombinant was based on the RBOK vaccine strain, which is avirulent in rabbits, carrying the haemagglutinin (H) protein gene from the lapinized RPV (RPV-L) strain, which is pathogenic in rabbits. The recombinant virus (rRPV-lapH) was rescued from a cDNA of the RBOK strain in which the H gene was replaced with that from the RPV-L strain. The recombinant grew at a rate equivalent to the RPV-RBOK parental virus in B95a cells but at a lower rate than RPV-L. The H gene swap did not affect the ability of the RBOK virus to act as a vaccine to protect cattle against virulent RPV challenge. Rabbits inoculated with RPV-L became feverish, showed a decrease in body weight gain and leukopenia. High virus titres and histopathological lesions in the lymphoid tissues were also observed. Clinical signs of infection were never observed in rabbits inoculated with either RPV-RBOK or with rRPV-lapH; however, unlike RPV-RBOK, both RPV-L and rRPV-lapH induced a marked antibody response in rabbits. Therefore, the H protein plays an important role in allowing infection to occur in rabbits but other viral proteins are clearly required for full RPV pathogenicity to be manifest in this species.

Plasmid vaccine pBK-CMVMPILC113 expressing the matrix (M) gene of rinderpest virus was assessed for its potential to protect rabbits against a lethal viral challenge. Rabbits immunized with plasmids expressing the M gene were not protected when challenged with lapinized rinderpest virus, despite the production of anti-M antibodies, while rabbits immunized with rinderpest tissue culture vaccine were completely protected from a lethal challenge with lapinized rinderpest virus. The plasmid vaccine also had no significant effect on the lymphopenia in challenged rabbits. The results indicate that rinderpest M protein does not have a protective role in rinderpest infection.

Cattle were vaccinated with a recombinant capripox-rinderpest vaccine designed to protect cattle from infection with either rinderpest virus (RPV) or lumpy skin disease virus (LSDV). Vaccination did not induce any adverse clinical responses or show evidence of transmission of the vaccine virus to in-contact control animals. Approximately 50% of the cattle were solidly protected from challenge with a lethal dose of virulent RPV 2 years after vaccination while at 3 years approx. 30% were fully protected. In the case of LSDV, all of 4 vaccinated cattle challenged with virulent LSDV at 2 years were completely protected from clinical disease while 2 of 5 vaccinated cattle were completely protected at 3 years. The recombinant vaccine showed no loss of potency when stored lyophylized at 4 degrees C for up to 1 year. These results indicate that capripoxvirus is a suitable vector for the development of safe, effective and stable recombinant vaccines for cattle.

Rinderpest is an acute and highly contagious viral disease of ruminants, often resulting in greater than 90% mortality. We have constructed a recombinant vaccinia virus vaccine (v2RVFH) that expresses both the fusion (F) and hemagglutinin (H) genes of rinderpest virus (RPV) under strong synthetic vaccinia virus promoters. v2RVFH-infected cells express high levels of the F and H glycoproteins and show extensive syncytium formation. Cattle vaccinated intramuscularly with as little as 10(3) PFU of v2RVFH and challenged 1 month later with a lethal dose of RPV were completely protected from clinical disease; the 50% protective dose was determined to be 10(2) PFU. Animals vaccinated with v2RVFH did not develop pock lesions and did not transmit the recombinant vaccinia virus to contact animals. Intramuscular vaccination of cattle with 10(8) PFU of v2RVFH provided long-term sterilizing immunity against rinderpest. In addition to being highly safe and efficacious, v2RVFH is a heat-stable, inexpensive, and easily administered vaccine that allows the serological differentiation between vaccinated and naturally infected animals. Consequently, mass vaccination of cattle with v2RVFH could eradicate rinderpest.

Rinderpest had been reported in most parts of Ethiopia when the Pan African Rinderpest Campaign (PARC) was launched. As a result of intensive disease investigation and strategic vaccination, most parts of the country are now considered provisionally free, and widespread vaccination has been replaced by clinical and serological surveillance. Details of any episodes of disease are recorded and followed up after laboratory confirmation of suspected cass using antigen-capture ELISA. This paper is based on observations on the performance of the antigen detection ELISA compared to the agar gel immunodiffusion (AGID) test, which also differentiates rinderpest from peste des petits ruminants (PPR). The stability of the specific viral antigen was monitored for 4 days, and rinderpest and PPR antigens were still detected, depending on the type of specimen. Antigen capture ELISA is more rapid, sensitive and virus specific than the AGID. Even if the cold chain of the specimen is compromised for a day or two during sample collection and submission, the specimen may still be suitable for testing by ELISA.

Rinderpest virus causes a highly contagious and often fatal disease in domestic and wild ruminants. The surface glycoproteins, hemagglutinin (H) and fusion (F) proteins of this enveloped virus are known to confer protective immunity in cattle. We have reported the generation of a recombinant baculovirus expressing H protein and studied its protective properties in cattle. In this report, we demonstrate that the recombinant baculovirus encoded H protein expressed in insect cells gets incorporated into extracellular baculovirus. Single administration of low doses of purified recombinant extracellular virus with or without adjuvant induces virus neutralizing antibody responses and bovine leukocyte antigen (BoLA) class II restricted helper T cell responses in cattle.

Rinderpest virus (RPV), a member of genus Morbillivirus in the family Paramyxoviridae, causes an acute and often fatal disease in cattle and other large ruminants. A subunit rinderpest vaccine consisting of an immune-stimulating complex (ISCOM) incorporating the RPV haemaggulutinin (H) protein, was examined for its ability to induce protective immunity in cattle, the natural host of RPV. All of four cattle vaccinated with the ISCOM vaccine survived challenge with virulent virus. Three were solidly protected, showing no clinical signs of infection, while the fourth animal developed only mild and transient symptoms. Virus neutralizing antibodies were produced at a significant level in all vaccinated cattle. These results indicate that this ISCOM vaccine is effective in producing protective immunity in cattle and should be a suitable means of delivering glycoprotein antigens from other morbilliviruses.

The nucleocapsid protein (N) of morbilliviruses is not only a major structural protein but also the most abundant protein made in infected cells. We overexpressed the N proteins of Rinderpest virus and Peste des petits ruminants virus in E. coli, which assemble into nucleocapsids in the absence of viral RNA that resemble nucleocapsids made in the virus-infected cells. Employing these assembled structures resembling subviral particles, we studied the induction of both the antibody response and the cytotoxic T-lymphocyte (CTL) response in a murine model (BALB/c). A single dose of the purified recombinant nucleocapsids of both viruses in the absence of an adjuvant induces a strong CTL response. The CTLs generated are antigen specific and cross-reactive with respect to each virus and, furthermore, this CTL response is MHC class I restricted. Based on the prediction for H-2(d)-restricted T-cell motifs we tested the lysis of transfected P815 (H-2(d)) cells expressing a nine amino acid potential CTL epitope, by splenic T cells in vitro restimulated with bacterially expressed RPV or PPRV N proteins. We extended our study to the bovine system both to analyze the immunogenicity of these recombinant proteins in the natural hosts and to show that PBMC from cattle vaccinated with Rinderpest vaccine proliferate in vitro, in response to restimulation with soluble nucleocapsid proteins. Furthermore, the murine CTL epitope functions in the bovine system as a cytotoxic T-cell epitope. This sequence, which is conserved in the N proteins of morbilliviruses, conforms well to the predicted algorithm for some of the most common BoLA CTL antigenic peptides., (Copyright 2001 Academic Press.)

Rinderpest virus (RPV) is a highly contagious and often fatal disease of domestic and wild ruminants, caused by rinderpest virus of the genus Morbillivirus under the family Paramyxoviridae. Hemagglutinin (H) and fusion (F) proteins of this enveloped virus confer protective immunity against experimental challenge with virulent rinderpest virus. We have earlier demonstrated that immunization with a single dose of recombinant extracellular baculovirus expressing H protein elicits H-specific humoral and lymphoproliferative responses in cattle. The lymphoproliferative responses are predominantly BoLA class II restricted. In this work, we have analyzed lymphoproliferative responses of peripheral lymphocytes from immunized cattle to truncated H protein fragments expressed in E. coli for locating domains harboring Th epitopes. One region (aa 113-182) recognized by immune T cells is conserved in the H protein of measles virus, which was earlier shown to contain a dominant Th epitope in mouse. Synthetic peptides within this region of measles virus H protein were used to identify a Th epitope conserved in the H protein of RPV virus (aa 123-137) in cattle. A second Th epitope located at the C-terminus of RPV-H was mapped to the region corresponding to aa 512-609 using truncated protein fragments expressed in E. coli. The C-terminal epitope (aa 575-583) was mapped using synthetic peptides corresponding to measles virus H as well as RPV-H protein.

A competitive enzyme-linked immunosorbent assay has been standardised for the detection of antibodies to rinderpest virus in sera from cattle, sheep and goats. The test uses a neutralising monoclonal antibody (MAb) directed against the haemagglutinin protein of rinderpest virus. The test is specific for rinderpest, as it failed to detect antibodies to peste des petits ruminants virus in convalescent goat sera. A 45% inhibition of the binding of the MAb to the antigen was used as the cut-off point for deciding the rinderpest status of the test samples. The specificity and sensitivity of the test and the stability of the test reagents were determined and compared to the results obtained using a commercial kit with approximately 1,200 serum samples from cattle, sheep and goats in India. The current test compared very well with the commercial kit. The test is expected to be extremely useful for sero-monitoring and sero-surveillance of rinderpest in countries which are actively pursuing a rinderpest eradication programme.

The accepted procedure for the long-term preservation of live viruses and bacteria in vaccines has been lyophilisation. We show that thermolabile viruses can be dehydrated in vitro, within 18 h, in an excipient containing trehalose. We further demonstrate that in the resulting dehydrated state, where the viruses are captive in a metastable glass composed of trehalose, they are capable of resisting 45 degrees C for a period of 14 days with minimal loss of potency. The degree of thermotolerance achieved matches that of current 'thermostable' lyophilised vaccines, but with the distinct advantage of a shorter, cheaper and simpler process. The development and utilisation of this process can make significant improvements in current live virus vaccine production. It presents a further step away from dependence on mandatory low temperature refrigerated storage and could lead to greater confidence in vaccine stability, potency and efficacy.

Dry powder tissue culture rinderpest vaccine containing 10(2.5) TCID(50) of virus per dose administered intranasally to cattle induced high titre circulating antibody responses and protection against challenge with a virulent strain of rinderpest virus. A reduction in the dose of virus to 10(1.1) TCID(50) resulted in a failure to elicit detectable antibody responses and a lack of protection. Intranasal powder vaccine offers several advantages over conventional needle-administered aqueous rinderpest vaccine, including greater stability in the absence of a cold chain, reduced risk of 'needle transfer' of other microbial agents present in the vaccinated herd and lower cost.

A recombinant vaccine, produced by using a highly attenuated smallpox vaccine (LC16mO) as a vector and which expresses the rinderpest virus (RPV) haemagglutinin protein, has been developed. The properties of this vaccine, including its heat stability, efficacy in short-term trials, safety and genetic stability, have been confirmed in an earlier report. In the present study, the duration of the protective immunity generated by the vaccine in cattle was examined for up to 3 years following the administration of a single vaccination dose of 10(8) p.f.u. The vaccinated cattle were kept for 2 (group I) or 3 years (group II) and then challenged with a highly virulent strain of RPV. Four of five vaccinated cattle in group I and all six cattle in group II survived the challenge, some showing solid immunity without any clinical signs of rinderpest. Neutralizing antibodies were maintained at a significant level for up to 3 years and they increased rapidly following challenge. Lymphocyte proliferative responses to RPV were examined in group II cattle and were observed in four of the six vaccinated cattle in this group. The long-lasting protective immunity, in addition to the other properties confirmed previously, indicate the practical usefulness of this vaccine for field use.

In order to effectively control and eliminate rinderpest, a method is required to allow serological differentiation between animals that have been vaccinated and those which have recovered from natural infection. One way of doing this would be to engineer the normal vaccine to produce a genetically marked rinderpest virus (RPV) vaccine. We constructed two modified cDNA clones of the RPV RBOK vaccine strain with the coding sequence of the green fluorescent protein (GFP) gene inserted as a potential genetic marker. RPVINS-GFP virus was designed to produce independent and high level expression of GFP inside infected cells, whilst the GFP expressed by RPVSIG-GFP virus was designed to be efficiently secreted. Infectious recombinant virus was rescued in cell culture from both constructs. The effectiveness of these viruses in stimulating protective immunity and antibody responses to the marker protein was tested by vaccination of cattle and goats. All of the vaccinated animals were completely protected when challenged with virulent virus: RPV in cattle or peste-des-petits ruminants virus in the goats. ELISA showed that all of the animals produced good levels of anti-RPV antibodies. Three of the four cattle and the two goats vaccinated with RPVSIG-GFP produced detectable levels of anti-GFP antibodies. In contrast, no anti-GFP antibodies were produced in the four cattle and two goats vaccinated with RPVINS-GFP. Therefore, secretion of the GFP marker protein was absolutely required to elicit an effective humoral antibody response to the marker protein.

An investigation was made into whether recent vaccination of cattle with tissue culture rinderpest virus would cause immunosuppression and lead to more frequent or more severe infection with trypanosomes in animals grazing in tsetse-infested areas. Herds of cattle on Galana Ranch in Kenya were divided, with approximately half of each herd being vaccinated with tissue culture rinderpest virus strain Kabete 'O', while the rest remained unvaccinated. The herds were then exposed to the risk of natural infection with trypanosomes on the ranch. Three experiments were performed during different seasons. Infections with Trypanosoma congolense and Trypanosoma vivax were frequently detected but there was no evidence that vaccinated animals were more likely to acquire trypanosome infections or to show a more severe disease than unvaccinated cattle. It is concluded that tissue culture rinderpest vaccine does not cause immunosuppression and can safely be used in cattle likely to be exposed to tsetse flies and trypanosomosis.

In January 1997, serum samples from 1346 adult sheep and goats were tested by a competitive ELISA to determine the prevalence of rinderpest in the northern zone of Tanzania. Seroconversion rates of 20%, 13%, 9%, 7% and 3% in sheep and goats were recorded in Ngorongoro, Monduli, Hai, Arumeru and Simanjiro districts, respectively. The low profile and insidious nature of the rinderpest virus involved caused very mild disease in cattle in some of these area. The mild signs associated with this outbreak of rinderpest resulted in difficulty in its diagnosis. In these circumstances, the presence of rinderpest antibody in sheep and goats served as a valuable and effective indicator of the rinderpest outbreak in cattle.

Approximately 0.2% (n = 4397) of the bovids (cattle and buffalo) in Sri Lanka were sampled, from June 1992 using a multi-stage sampling procedure. Serum antibodies for the rinderpest virus were detected using the competitive enzyme-linked immunosorbent assay. The age, the agroclimatic zone, the management system practiced in the farms, and the vaccination history of the sampled bovids were studied as potential risk factors for being seropositive. The prevalence of rinderpest antibodies in non-vaccinated bovids was 3.5% (n = 4101). The prevalence was higher in the dry zone (9%; where the outbreak emerged in 1987), compared to bovids in the other zones (1%). Seropositive bovids over three years of age were approximately at fourfold higher chances of being seropositive compared to those that were < or = 3 years old. The higher prevalence in older animals is probably due to exposure to the virus during the 1987 epidemic. Bovids from the dry zone (annual rainfall 20 to 35 inches) were at higher odds of being seropositive even after controlling for the possible effects of age, agroclimatic zone, management system and vaccination. The fact that 62% of bovids from the dry zone in this study were reared under extensive management system (free grazing) which allow unrestricted contact between animals, may be the reason for the above finding. A relatively poor response to vaccination observed in vaccinated bovids (seroprevalence = 12%; n = 296) could be attributed to difficulties in maintaining the vaccine at recommended temperatures in the field. This is the first island-wide study on seroprevalence of rinderpest in Sri Lanka.

Haemagglutinin (HA) and fusion (F) proteins of peste-des-petits-ruminants virus (PPRV) and rinderpest virus (RPV) were purified by immunoaffinity chromatography. The purified proteins were characterized by polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate (SDS-PAGE). Rabbit hyperimmune sera were raised against the purified HA and F proteins and assayed by enzyme-linked immunosorbent assay (ELISA), haemagglutination-inhibition (HAI) and virus neutralization (VN) tests. The immunized animals were challenged with a virulent lapinized (rabbit-adapted) strain of RPV. Both HA and F proteins of PPRV protected rabbits against a lethal challenge with lapinized RPV. As expected, RPV HA and F proteins also conferred a similar protection against the homologous challenge. The postchallenge antibody responses were of a true anamnestic type.

Rinderpest is a scourge continuing to change the course of history. The German "Rinderpest" in English fails to convey the spectre of Death, Despair and Desolation long associated with the disease. Although the causal morbillivirus cross-protects against other morbillivirus, there is only one rinderpest serotype which is both immuno-suppressive and immunogenic. Safe vaccines induce lifelong protection in cattle. Transmission follows close contact between sick and healthy artiodactyls. Infectious periods are short and deaths may be curtailed by liberal fluid replacement therapy. Carriers do not exist. In other words rinderpest is a prime candidate for eradication. Why has it not happened? The major obstacle is "man's inhumanity to man". Rinderpest thrives in a milieu of armed conflict and fleeing refugee masses. Until world peace is secured, the "Nays" win the argument.

The Karimojong CAHW program, in which members of the pastoral Karimojong community were trained as basic veterinary care providers, was evaluated using ethnoveterinary techniques. A serological study of rinderpest antibody titers was also completed to compare serological results with ethnoveterinary results in the case of one disease, rinderpest. An outbreak of rinderpest-like disease that occurred during the field phase of the study was also investigated. The results show that rinderpest does exist in Karamoja in an apparently endemic form. Given the significant value placed by Karimojong herders on vaccinated animals, it can be concluded that they would adequately vaccinate their herds if they could trust the vaccine and the vaccinator. Discrepancies between ethnoveterinary and serological results show that ethnoveterinary techniques do not provide numerically accurate data concerning protection from disease, but that they can, nonetheless, provide basic, cost effective indications of disease patterns.

Recombinant vaccinia virus (rVV) was constructed by inserting Rinderpest Virus (RPV) nucleocapsid (N) protein gene. The rVV expressed RPV-N protein in the rVV-infected cells. The rVV was shown to produce RPV-N-specific antibody in mice.

A recombinant vaccinia virus (RVV) expressing the nucleoprotein (NP) of rinderpest virus (RPV) was examined in rabbits for the involvement of the NP protein in protection from the RPV infection. Despite their production of anti-NP antibody, the RVV-immunized rabbits succumbed to the RPV challenge, although there was a slight delay in the onset of disease after the low-dose challenge. On the other hand, the animals immunized with RVV expressing the hemagglutinin (H) protein of the RPV were completely protected. These results indicate that the NP protein might be not so effective as the H protein for the protection against viremic and systemic infection with RPV.

Using the competitive enzyme-linked immunosorbent assay for the seromonitoring of rinderpest in Saudi Arabia, antibodies were detected in 30% of the sera of 1,018 cattle slaughtered at Riyadh abattoir during June and July 1995. The correlation between the detection of antibodies and the origins of the slaughtered animals was analysed. All the culled dairy cows had detectable antibodies. The proportions of bulls giving serologically positive results were as follows: 57% for animals imported from rinderpest-free countries and vaccinated upon arrival in Saudi quarantine, 20% for native breeding animals and 17% for five- to ten-month-old bull calves born on commercial dairy farms and then raised on separate feedlot farms. In addition, of 105 native cattle sacrificed during the Hajj season in May 1994, 77% had antibodies against rinderpest virus. On the other hand, testing of 17 groups of dairy heifers (from 1 week to 24 months of age), born to immune dams and vaccinated against rinderpest at the ages of six and ten months, revealed the absence of detectable antibodies in the sera of some animals which were between two and ten months of age. Results are interpreted in relation to evaluation of the continuing vaccination programmes and their efficacy as an element of the national programme for the control of rinderpest.

A dot-immunobinding (DIB) assay was used to detect rinderpest antibodies in cattle vaccinated with Kabete 'O' strain vaccine, using purified rinderpest virus. Of 120 serum samples from vaccinated and non-vaccinated animals, rinderpest antibodies were detected in 80%, 88.4% and 91.6% of samples at 2, 3 and 4 weeks postvaccination respectively. All the serum samples from non-vaccinated animals were negative. The DIB results had a good correlation with those of the micro neutralisation test. The technique is simple, easy to perform and suitable for routine use in detecting rinderpest antibodies following vaccination.

The sequence of the hemagglutinin (HA) gene of the LA strain of rinderpest virus (RPV) has been determined by the direct sequencing method. The amino acid sequence of the protein which it encodes displays conservation of its structural determinants with the HA proteins of the other RPV strains. The LA-HA protein was shown to have three conserved potential N-linked glycosylation sites, compared with four such sites in the HA protein of L strain. The glycosylation site at position 200 on the L-HA molecule is absent from its LA-HA counterpart, due to a lysine for an asparagine substitution. The HA proteins of L and LA strains were the same molecular weight as judged by mobility on SDS-PAGE, suggesting that the site at position 200 is not used for glycosylation.

The national veterinary Laboratory, Garoua (Cameroon) has been carrying out rinderpest sero-surveillance since 1989 as part of an effort made by the Panafrican Rinderpest Campaign (PARC) to control rinderpest in Africa. In 1993, 8517 serum samples collected from 286 cattle herds (from 0 to 3 years old) randomly chosen from six provinces with large cattle population (Far-North, North, Adamaoua, East, West, North-West) were tested using the rinderpest competitive ELISA technique; the herd immunity level was 54%. Out of 2010 serum samples from 68 non-protected cattle herds tested using the peste des petits ruminants (PPR) ELISA technique, 91 samples were positive (4.5%): this does not significantly increase the cattle immunity level against rinderpest. Significant differences in the immunity rates between provinces were observed. Suggestions to increase the immunity level are discussed.

The ability of the attenuated peste des petits ruminants vaccine virus to protect small ruminants against virulent rinderpest virus was investigated. Out of four susceptible goats that were infected with the highly virulent Saudi strain of rinderpest virus by intranasal ioculation, three developed mild clinical signs of disease and infected susceptible in-contact goats and cattle with rinderpest virus. However, four goats which had been vaccinated with the attenuated peste des petits ruminants virus resisted challenge with virulent rinderpest virus and did not infect susceptible in-contact animals.

Isolates of rinderpest virus (RPV) recovered from outbreaks of the disease in Kenya and Southern Sudan between 1986 and 1993 were compared to each other and to earlier isolates from East and West Africa. The recent isolates were mildly pathogenic for susceptible cattle and thus resembled other mild strains of RPV recovered from cattle and wildlife in East Africa more than 30 years ago. Monoclonal antibody analysis using a panel of 12 anti-RPV haemagglutinin protein-specific antibodies (mAbs) revealed that individual isolates were distinguishable. However, the panel of mAbs could not be used to relate the isolates on the basis of their pathogenicity or geographic origin. Immunoprecipitation of the virus-induced proteins from infected Vero cells, followed by SDS-polyacrylamide gel electrophoresis, showed that the recent mild RPV isolates from eastern Africa were closely related to each other and to their contemporary isolates from Nigeria and Egypt, but they were distinct from another mild isolate recovered from the region three decades ago. Two distinct lineages of African RPV isolates were identified by sequencing a region of the genome around the proteolytic enzyme cleavage site of the fusion protein from the old and new isolates. One lineage, which included virus isolates recovered from East and West Africa during the 1960s, showed a closer phylogenetic relationship to Asian and Middle Eastern RPV isolates. The other lineage consisted mainly of isolates recovered from East, West and North Africa between 1983 and 1993. The results showed that there was co-circulation of two different lineages of RPV in Nigeria during the epizootics of the 1980s.

Experimental infection of nine cattle with seven rinderpest virus strains of different pathogenicity resulted in significant variations of clinical signs, morphological lesions and distribution of viral antigen in tissues. The severity of clinical disease was correlated with the extent of tissue alterations and the amount of immunohistologically detectable viral antigen. Both mild and virulent strains of rinderpest share essentially the same tissue tropisms in vivo, i.e. epithelio- and lympho-tropism. However, rinderpest virus isolates of higher pathogenicity showed a more rapid and wider distribution with more extensive lesions than milder strains, which probably accounts for the higher mortality.

Humoral antibody responses in cattle or rabbits infected with virulent rinderpest virus or lapinised rinderpest virus respectively were assessed. Rinderpest specific antibodies could be first detected 6 days post-infection. No correlation could be established between antibody response and the course of the disease in infected animals during the early stages of infection. The animals with fatal infection either did not respond or had a transient antibody response. A gradual increase in antibody titre from 7 days post-infection was observed in animals which ultimately recovered.

The pathogenesis of infection with the L-strain of rinderpest virus (RPV) in rabbits was investigated. Of several lymphoid tissues examined, those associated with the gut showed the most marked virus growth. The virus titres were maximal 4 days after inoculation but had declined at day 6. The distribution of viral antigen was examined immunohistochemically with the recently established anti-rabbit CD5 monoclonal antibody (MoAb), which is a pan-T-cell marker, and the anti-RPV-nucleoprotein MoAb. The virus antigen was localized in the CD5+ area at the initial stage of infection but spread to all areas of the lymphoid tissues at the later stages. By flow cytometric analysis with both rabbit CD5 and CD4 MoAbs, a decrease of the CD4+ and CD5+ subpopulations was observed in the spleen and mesenteric lymph nodes.

A cDNA clone containing the complete coding sequence of the hemagglutinin (H) protein gene of the RBOK vaccine strain of rinderpest virus, under the control of the vaccinia late promoter p11, was inserted by homologous recombination into the thymidine kinase gene of the KS-1 strain of capripoxvirus. The recombinant virus produced authentic H protein as judged by its electrophoretic mobility, transport to the cell surface of infected lamb testis cells, and reactivity with monoclonal antibodies specific for the H protein of rinderpest virus. The recombinant virus induced significant levels of rinderpest virus neutralizing antibodies in vaccinated cattle and protected them from clinical rinderpest after challenge with a lethal dose of a highly virulent heterologous strain of the virus. Protection was achieved using vaccine doses lower than those used with a similar recombinant expressing the fusion protein gene of rinderpest. The parental KS-1 virus is widely used as a vaccine against capripox viruses and so the rinderpest recombinant acts as a dual vaccine to protect cattle against both rinderpest and lumpy skin disease.